Key result
TAVR showed no significant difference compared to SAVR in early mortality or late mortality among patients of moderate or high surgical risk.
Why the study?
Does transcatheter aortic valve replacement improve major adverse outcomes compared to surgical aortic valve replacement in moderate and high-risk patients?
Meta-Analysis (n=20,224)
Does transcatheter aortic valve replacement improve major adverse outcomes compared to surgical aortic valve replacement in moderate and high-risk patients?
TAVR and SAVR offer similar short and long-term mortality and stroke risks in moderate to high-risk patients, with TAVR reducing bleeding and acute kidney injury but increasing pacemaker need and vascular complications.
Answers are grounded in this paper and cite their sources.
Supports individualized TAVR or SAVR selection in moderate/high-risk patients; confirms mortality equivalence from prior RCTs.
Objectives: The evidence of the benefits of transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR) for patients of high or intermediate surgical risk is not consistent. We performed a meta-analysis to compare major adverse outcomes after TAVR or SAVR. Methods: We searched propensity score matched studies or randomized clinical trials comparing the risks of mortality, stroke, major bleeding, acute renal injury, pacemaker implantation, vascular complications and prostheses haemodynamic performance between TAVR and SAVR in patients with moderate or high risk. Combined odds ratios (ORs), relative risk or mean differences with corresponding 95% confidence intervals (CIs) were calculated using a random effects model. Analyses of sensitivity and publication bias were also conducted. Results: We included 5 clinical trials and 37 observational studies, enrolling 20 224 patients (TAVR, n = 9099 and SAVR, n = 11 125). The pooled analysis suggested no differences in early (OR = 1.11, 95% CI 0.9-1.39, P = 0.355) or late mortality (relative risk = 0.91, 95% CI 0.78-1.05, P = 0.194). TAVR was associated with a lower risk of major bleeding (OR = 0.42, 95% CI 0.25-0.69, P < 0.001) and acute kidney injury (OR = 0.51, 95% CI 0.34-0.71) but with an increase in the incidence of pacemaker implantation (OR = 2.31, 95% CI 1.73-3.08) and vascular complications (OR = 4.88, 95% CI 2.84-8.39). Residual aortic regurgitation was more frequent after TAVR (OR= 6.83, 95% CI 4.87-9.6). SAVR prostheses were associated with poor trans-prosthetic gradients (mean difference: -2.4 mmHg, 95% CI - 3.27 to - 1.53). Conclusions: TAVR and SAVR have similar short and long-term all-cause mortality and risk of stroke among patients of moderate or high surgical risk. TAVR decreases the risk of major bleeding, acute kidney injury and improves haemodynamic performance compared with SAVR but increases the risk of vascular complications, the need for a pacemaker and residual aortic regurgitation.
No takes yet. Share an insight, caveat, or question.
Carnero et al. (2016) conducted a meta-analysis in Moderate or high surgical risk requiring aortic valve replacement (n=20,224). Transcatheter aortic valve replacement (TAVR) vs. Surgical aortic valve replacement (SAVR) was evaluated on Early mortality (OR 1.11, 95% CI 0.9-1.39, p=0.355). TAVR showed no significant difference compared to SAVR in early mortality or late mortality among patients of moderate or high surgical risk.
Synapse has enriched 10 related papers. Consider them for comparative context: